Photo take fro Mark Wildgust/LinkedIn
Jul 2, 2024, 08:55
Mark Wildgust: Another incredible milestone for our JNJOncology team!
Mark Wildgust, The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:
“Another incredible milestone for our JNJOncology team!.
As this team continues to make strides to advance the science of Lung Cancer, I look forward to what’s to come in the treatment of this disease.”
Read further.
Source: Mark Wildgust/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 12:14
Nov 14, 2024, 12:09
Nov 14, 2024, 11:56
Nov 14, 2024, 11:49
Nov 14, 2024, 11:46
Nov 14, 2024, 11:38
Nov 14, 2024, 11:30
Nov 14, 2024, 09:31
Nov 14, 2024, 09:26